Wednesday, December 6, 2017 at 12:15 a.m. CT

• Ribociclib Improved Progression-free Survival for Pre- and Perimenopausal Women With Hormone Receptor positive Advanced Breast Cancer
• Immunotherapy Shows Early Promise for Patients With Trastuzumab-resistant Breast Cancer

Thursday, December 7, 2017 at 7:30 a.m. CT

• Two Years of Extended Anastrozole Therapy Proved as Effective as Five Years in Clinical Trial
• Phase III Trial Data Support Current Standard 12-month Adjuvant Trastuzumab for HER2-positive Breast Cancer*
• Temporary Ovarian Suppression With Hormone Analog May Preserve Fertility During Breast Cancer Chemotherapy
• Acupuncture Reduced Joint Pain Caused by Aromatase Inhibitor Treatment in a Randomized, Phase III Clinical Trial

Friday, December 8, 2017 at 7:30 a.m. CT

• Older Women with HR-positive Breast Cancer May Receive Similar Benefit from CDK 4/6 Inhibitors as Younger Women
• Postmenopausal Women Who Lose Weight May Have Reduced Breast Cancer Risk
• Circulating Tumor Cells May Predict Late Recurrence in HR-positive Breast Cancer Patients
• Phase III EMBRACA Trial Meets Primary Endpoint

Friday, December 8, 2017 at 9:30 a.m. CT

• Lymph Node Surgery May Raise Risk of Arm Morbidity in Younger Women